Structure Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights
May 11, 2023 16:30 ET
|
Structure Therapeutics Inc.
Oral GLP-1 agonist GSBR-1290 advancing into Phase 2a study in type 2 diabetes and obesity Topline data from Phase 1b multiple ascending dose and Phase 2a studies of GSBR-1290 expected in second half...
Structure Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights
March 30, 2023 16:30 ET
|
Structure Therapeutics Inc.
Completed dosing of Phase 1b study of oral GLP-1 agonist GSBR-1290Topline data from Phase 1b and Phase 2a studies of GSBR-1290 expected in 2H 2023Completed $185.3 million upsized initial public...
Pulmonary Arterial Hypertension Market Worth ($10.88 Billion by 2028) Lead by Asia Pacific Region (6.5% CAGR) – Global Report by The Insight Partners
February 28, 2023 09:03 ET
|
The Insight Partners
New York, Feb. 28, 2023 (GLOBE NEWSWIRE) -- According to The Insight Partners, “Pulmonary Arterial Hypertension Market Size, Share, Growth, Trends and Global Forecast to 2028 - COVID-19 Impact and...
硕迪生物宣布完成经增发的首次公开募股包括承销商全面行使购买额外美国存托股票的选择权
February 07, 2023 16:00 ET
|
Structure Therapeutics Inc.
旧金山和上海, Feb. 08, 2023 (GLOBE NEWSWIRE) --...
Structure Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional American Depositary Shares
February 07, 2023 16:00 ET
|
Structure Therapeutics Inc.
SAN FRANCISCO and SHANGHAI, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule...
硕迪生物宣布经增发的首次公开募股的定价
February 02, 2023 20:59 ET
|
Structure Therapeutics Inc.
加利福尼亚州旧金山和中国上海, Feb. 03, 2023 (GLOBE NEWSWIRE) -- 硕迪生物技术有限公司（纳斯达克股票代码：GPCR）是一家临床阶段的全球化生物制药公司，致力于口服小分子药物的创新研发以治疗代谢性和肺部疾病。今日，公司宣布其经增发的首次公开募股的定价。公司拟发行10,740,000股美国存托股票（ADS），每股ADS代表三股普通股，公开发行价格为每股ADS...
Structure Therapeutics Announces Pricing of Upsized Initial Public Offering
February 02, 2023 19:41 ET
|
Structure Therapeutics Inc.
SAN FRANCISCO and SHANGHAI, China, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small...
APEIRON Respiratory Therapies announces positive results from Phase I trial of inhaled APN01
November 03, 2022 03:00 ET
|
invIOs GmbH
Administration of aerosolized APN01 shown to be safe and well tolerated at all dose levels, with no adverse events above Grade 2Investigators recommend further development of inhaled APN01, which may...
The First PHantasticals Come to Life to Raise Awareness of Pulmonary Hypertension
May 05, 2022 05:00 ET
|
Ferrer
BARCELONA, Spain, May 05, 2022 (GLOBE NEWSWIRE) -- Coinciding with World Pulmonary Hypertension (PH) Day, which is celebrated every May 5, Ferrer and the European Pulmonary Hypertension Association...
Liquidia Reports First Quarter 2020 Financial Results and Provides Corporate Update
May 11, 2020 16:01 ET
|
Liquidia Technologies, Inc.
Received FDA Acceptance of LIQ861 NDA for ReviewReported Final Safety and Tolerability Results for LIQ861 Inspire TrialManagement to Host Webcast and Conference Call Today at 4:30p.m. ET ...